Ana F.
- Country
- Portugal
- Department
- Serviço de Oncologia Médica
Research Overview
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
- Efficacy and Safety of Pembrolizumab with Chemoradiotherapy versus Chemoradiotherapy Alone in Muscle-Invasive Bladder Cancer: A Phase III Randomized Trial
Data & Insights
Has run more than one trial at 13 of 70 partner sites.
Specializations
Oncological Focus
The investigator specializes in treating complex urological and gastrointestinal malignancies, with particular emphasis on innovative therapeutic approaches for aggressive forms of cancer.
- Esophageal carcinoma management
- Muscle invasive bladder cancer treatment
Their clinical interests encompass the integration of targeted therapies with traditional treatment modalities.
Treatment Approaches
The investigator focuses on combined therapeutic strategies incorporating chemoradiotherapy with immunotherapy interventions.
- Definitive concurrent chemoradiotherapy protocols
- Bladder-preserving treatment strategies
- Immunotherapy integration
Their expertise includes the development of organ preservation approaches in cancer treatment.
Therapeutic Innovation
The investigator's work centers on advancing personalized treatment approaches through biomarker-guided therapy selection.
- PD-L1 expression analysis
- Combined modality treatments
- Response assessment protocols
Their approach encompasses comprehensive evaluation of treatment efficacy through multiple assessment methods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.